OrganOx
Oxford, GB · 8 known investors
Find your way into OrganOx
OrganOx develops the metra platform, a device that extends organ preservation time for liver transplants by maintaining continuous perfusion with oxygenated blood-based solutions, enabling surgeons to better assess organ viability and make more informed transplant decisions.
Founders & leadership
PP
Prof. Peter FriendCo-Founder
Investors · 8
Amadeus Capital PartnersLondon · $50K – $12.7Mvia Craig Marshall · led
Business Growth FundLondon · $3.8M – $38M
HealthQuest CapitalRedwood City
Intuitive VenturesSunnyvale
Lauxera Capital PartnersParis · $22M – $110M
Longwall Venture Partners LLPHarwell · $2M
Oxford University InnovationOxford
Perivoli InnovationsSt. Helier
Funding
SEC filings, press & company announcements- Undisclosed amountgrowth roundJul 2023
Lauxera Capital Partners (lead)
Source ↗
Source: company announcements and press reports — follow each round's link for the claim.
Founder mafia
5 people who came through OrganOx went on to found or lead other companies.
Companies House · registry record
View on Companies House ↗- Registered name
- ORGANOX LIMITED
- Company number
- 06557113
- Status
- Active
- Company type
- Private limited company
- Incorporated
- 7 Apr 2008
- Registered office
- 125 Wood Street, London, EC2V 7AW
- Nature of business (SIC)
- 72190 — Other research and experimental development on natural sciences and engineering
- Accounts
- last made up to 31 Dec 2024 · next due 31 Dec 2026
- Confirmation statement
- last made up to 7 Apr 2026 · next due 21 Apr 2027
Current officers · 6
- Annabel Andrew — secretary, appointed 1 May 2025
- Jin Hagimoto — director, appointed 29 Oct 2025
- Takuya Hosokai — director, appointed 29 Oct 2025
- Naoya Iwata — director, appointed 1 Jun 2026
- Norimasa Kunimoto — director, appointed 29 Oct 2025
- Bhawna Menghnani — director, appointed 1 Apr 2026
Source: Companies House public register · retrieved 13 Sept 2026. Contains public sector information licensed under the Open Government Licence v3.0.
In the news
Frequently asked questions
- What does OrganOx do?
- OrganOx develops the metra platform, a device that extends organ preservation time for liver transplants by maintaining continuous perfusion with oxygenated blood-based solutions, enabling surgeons to better assess organ viability and make more informed transplant decisions.
- Who founded OrganOx?
- OrganOx was founded by Prof. Peter Friend.
- Who are OrganOx's investors?
- OrganOx's investors include Amadeus Capital Partners, Business Growth Fund, HealthQuest Capital, Intuitive Ventures, Lauxera Capital Partners, Longwall Venture Partners LLP, Oxford University Innovation, Perivoli Innovations.
- Where is OrganOx headquartered?
- OrganOx is headquartered in Oxford, GB.